Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 185.97

-0.4%

Feb 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Abuckatatime who wrote (6610)	9/17/1997 1:42:00 AM
From: Henry Niman	of 32384

Greg, Speaking of CNBC, they had a story on this evening regarding the Redux/Phenfluramine recall. Although the recall leaves a void in the treatement of obesity (which would be a plus for LGND), it probably will make approvals in that area more difficult. My concern was in the area of FDA reform, particularly off label use. That area really shouldn't be impacted, because it wasn't the phen/fen unapproved combo that was causing the heart problems because the fen part isn't being recalled. The combo arguement was just an AHP/IPIC ploy to distance themselves (put the FDA betweem them and the end users) from the liability law suits. CNBC also didn't see a major impact on FDA reform legislation. It was on track (with bipartisan support) and it did include a provision that allowed drug manufacturers to promote off label uses, which would be a decided plus for early diabetes indications for Targretin (it will be approved for cancer before its approved for diabetes).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next